Jump Financial LLC Makes New Investment in Tempus AI, Inc. $TEM

Key Points

• Jump Financial LLC has acquired a new position in Tempus AI, Inc., purchasing 177,135 shares valued at approximately $8.55 million.
• Major institutional investors, including ARK Investment Management and Vanguard Group, have significantly increased their holdings in Tempus AI, indicating strong interest in the stock.
• Tempus AI recently reported a quarterly revenue increase of 89.5% year-over-year, surpassing analysts' expectations with revenues of $314.64 million.

Jump Financial LLC acquired a new position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 177,135 shares of the company's stock, valued at approximately $8,545,000. Jump Financial LLC owned 0.10% of Tempus AI at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. ARK Investment Management LLC lifted its holdings in Tempus AI by 35.9% in the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock worth $361,867,000 after buying an additional 1,981,755 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 6,247.5% during the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after purchasing an additional 5,900,668 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 31.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after purchasing an additional 1,021,460 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after purchasing an additional 1,016,384 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its holdings in shares of Tempus AI by 236.2% during the fourth quarter. Frontier Capital Management Co. LLC now owns 943,718 shares of the company's stock valued at $31,860,000 after purchasing an additional 663,018 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $80.52 on Friday. Tempus AI, Inc. has a twelve month low of $31.36 and a twelve month high of $91.45. The firm has a market cap of $13.99 billion, a P/E ratio of -67.66 and a beta of 4.98. The company has a 50 day moving average of $63.78 and a 200 day moving average of $59.15. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. During the same period in the previous year, the business earned ($6.86) EPS. The firm's revenue for the quarter was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, research analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Insider Buying and Selling

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $70.07, for a total value of $17,517,500.00. Following the completion of the sale, the chief executive officer owned 9,357,283 shares of the company's stock, valued at approximately $655,664,819.81. The trade was a 2.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James William Rogers sold 7,528 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the sale, the chief financial officer directly owned 138,473 shares of the company's stock, valued at approximately $10,337,009.45. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold 776,451 shares of company stock worth $53,022,688 over the last 90 days. 27.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

TEM has been the subject of several recent research reports. Morgan Stanley lifted their target price on shares of Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Bank of America lifted their target price on shares of Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, June 25th. Guggenheim lifted their target price on shares of Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a report on Monday, June 30th. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a report on Friday, August 8th. Finally, BTIG Research lifted their target price on shares of Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $67.64.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.